- Molecular NameDelavirdine
- SynonymDLV; SPP
- Weight378.48
- Drugbank_IDDB00705
- ACS_NO136817-59-9
- Show 3D model
- LogP (experiment)2.92
- LogP (predicted, AB/LogP v2.0)2.58
- pka4.5
- LogD (pH=7, predicted)2.42
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.47
- LogSw (predicted, AB/LogsW2.0)0.12
- Sw (mg/ml) (predicted, ACD/Labs)4.82
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds4
- TPSA90.28
- StatusFDA approved
- AdministrationN/A
- PharmacologyA non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Pfizer. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate.
- Absorption_valueN/A
- Absorption (description)Delavirdine is rapidly absorbed after oral administration
- Caco_2N/A
- Bioavailability85.0
- Protein binding97.71
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP3A4- and CYP2D6-mediated). Extensively metabolised in the liver by the cytochrome P450 3A isoenzymes. Absorption is at least 45%.
- Half life2~11 h
- ExcretionIt is excreted as the metabolites in urine and faeces with <5% as the unchanged drug in urine.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityMajor toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.
- LD50 (rat)N/A
- LD50 (mouse)N/A